Market Turmoil Following Novo Nordisk's Announcement

The OMX Copenhagen Benchmark Index (OMXCB) experienced a dramatic drop of over 10% on Tuesday, marking its most significant one-day decline in years. This downturn was primarily fueled by a steep sell-off in shares of Novo Nordisk A/S, a leading pharmaceutical company.

Revised Forecasts Lead to Investor Panic

Novo Nordisk's stock plummeted more than 22% after the company revised its 2025 sales growth forecast downward. The new estimate ranges between 8% and 14%, a considerable decrease from the previous projection of 13% to 21% announced in May.

Immediate Market Reaction

By 3:11 pm CET, the shares of Novo Nordisk were trading at 349.25 Danish kroner, reflecting a 22.44% decrease. This event has sent ripples through the market, raising concerns among investors about the pharmaceutical sector's stability.